| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 and Restores the Lymphokine-Activated Killing Activity1
Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwan, Republic of China
IL-6 is a multifunctional cytokine that regulates cell growth, differentiation, and cell survival. Many tumor cells produce TGF-
1, which allows them to evade CTL-mediated immune responses. IL-6 antagonizes TGF-1 inhibition of CD3 cell activation. However, whether IL-6 restores NK activity, which also is suppressed by TGF-1, is not known. We used canine transmissible venereal tumor (CTVT), which produces TGF-1, as a model to determine whether IL-6 restores lymphokine-activated killer (LAK) activity. During the progression phase, CTVT cells stop expressing MHC molecules. During the regression phase, the number of surface MHC molecules increases dramatically on about one-third of tumor cells. Tumor cells that stop expressing MHC should be targeted by NK cells. In this study, we found that TGF-1 secreted by CTVT cells suppressed LAK cytotoxicity. Interestingly, tumor-infiltrating lymphocytes (TIL) isolated from regressing CTVT secrete high concentrations of IL-6 and antagonize the anti-LAK activity of tumor cell TGF-1. TIL also produce IL-6 during progression phase, but the concentration is too low to block the anti-LAK activity of TGF-1. There is probably a threshold concentration of IL-6 needed to reverse TGF-1-inhibited LAK activity. In addition, in the absence of TGF-1, IL-6 derived from TIL does not promote the activity of LAK. This new mechanism, in which TIL manufacture high concentrations of IL-6 to block tumor TGF-1 anti-LAK activity, has potential applications in cancer immunotherapy and tumor prognosis.
This article has been cited by other articles:
|
|
 |
|
  Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, and H. FUJII Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme Anticancer Res, June 1, 2009; 29(6): 2137 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Huang, S.-W. Hung, T.-R. Jan, K.-W. Liao, C.-H. Cheng, Y.-S. Wang, and R.-M. Chu CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells J. Leukoc. Biol., December 1, 2008; 84(6): 1501 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. Siddle, A. Kreiss, M. D. B. Eldridge, E. Noonan, C. J. Clarke, S. Pyecroft, G. M. Woods, and K. Belov From the Cover: Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial PNAS, October 9, 2007; 104(41): 16221 - 16226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Liu, J.-P. Tsai, C.-R. Shen, Y.-P. Sher, C.-L. Hsieh, Y.-C. Yeh, A.-H. Chou, S.-R. Chang, K.-N. Hsiao, F.-W. Yu, et al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-{beta} and interleukin-6 J. Leukoc. Biol., August 1, 2007; 82(2): 354 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Coleman, A. Clayton, M. D. Mason, B. Jasani, M. Adams, and Z. Tabi Recovery of CD8+ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian Cancer Cancer Res., August 1, 2005; 65(15): 7000 - 7006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Barakonyi, M. Rabot, A. Marie-Cardine, M. Aguerre-Girr, B. Polgar, V. Schiavon, A. Bensussan, and P. Le Bouteiller Cutting Edge: Engagement of CD160 by its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset J. Immunol., November 1, 2004; 173(9): 5349 - 5354. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
